Skip to main content

“Catheter Precision, Inc. (NYSE American: VTAK) Achieves 50 Patents Milestone for LockeT, Unveils Leadership Transition”

Catheter Precision, Inc. (NYSE American: VTAK), a prominent U.S.-based medical device company specializing in electrophysiology products, recently disclosed that it has secured approval for two new patents in the European market and Great Britain. This development is expected to significantly enhance the company's intellectual property portfolio, particularly concerning its LockeT line of products. 

In addition to a patent granted in Japan in 2023, the recent patents for LockeT bring the total number of issued patents and patent applications to 50. This milestone is indicative of the company's dedication to developing and preserving the distinctive features of its closure product design. The design is already accessible in the United States and is currently undergoing review for the CE Mark designation.

 Catheter Precision made significant updates to its board of directors and executive management on January 3, which also involved a change in the Chief Financial Officer position. The company disclosed the termination of Mr. Passey's employment at Catheter Precision, effective December 31, 2023. Subsequent to this decision, the Board of Directors appointed Margrit Thomassen, CPA, as the interim Chief Financial Officer. 

The interim CFO appointment became effective on January 2, 2024. Thomassen, who has been a full-time employee at a Catheter Precision subsidiary since 2019, was highlighted as a crucial contributor to the company during her tenure. Notably, she assumed the role of controller after Ra Medical acquired Catheter Precision in January of the previous year. 

Moreover, David Jenkins, the interim Chief Executive Officer, officially assumed the role of Chief Executive Officer as of January 2, 2024, while retaining his position as Chairman of the Board. In a development as of December 28, 2023, Susanne Meline resigned from the company's board of directors. 

As of January 2, 2024, John Francis took over the position previously held by Meline. The announcement highlighted that Francis, a managing member of Francis Capital Management LLC, assumed the role. Established in 2000, Francis Capital Management LLC specializes in small-cap stocks. With over two decades of experience in finance, accounting, and financial management, Francis brings significant expertise in the medical device industry, particularly with companies featuring a small market capitalization.

 

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.